Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Sodium glucose transporter-2 inhibitors reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus and a history of atherosclerotic cardiovascular disease. Because of their baseline risk, patients with previous myocardial infarction (MI) may derive even greater benefit from sodium glucose transporter-2 inhibitor therapy.

Related collections

Most cited references 15

Record: found
Abstract: found
Article: not found

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.

Aidin Rawshani, Araz Rawshani, Stefan Franzen … (2017)

Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes.

0 comments Cited 439 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

Subodh Verma, John J V McMurray (2018)

Sodium-glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular events, particularly heart failure, in cardiovascular outcome trials. Here, we review the proposed mechanistic underpinnings of this benefit. Specifically, we focus on the role of SGLT2 inhibitors in optimising ventricular loading conditions through their effect on diuresis and natriuresis, in addition to reducing afterload and improving vascular structure and function. Further insights into the role of SGLT2 inhibition in myocardial metabolism and substrate utilisation are outlined. Finally, we discuss two emerging themes: how SGLT2 inhibitors may regulate Na+/H+ exchange at the level of the heart and kidney and how they may modulate adipokine production. The mechanistic discussion is placed in the context of completed and ongoing trials of SGLT2 inhibitors in the prevention and treatment of heart failure in individuals with and without diabetes.

0 comments Cited 337 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry.

Matthew Cavender, Ph. Steg, Sidney Smith … (2015)

Despite the known association of diabetes mellitus with cardiovascular events, there are few contemporary data on the long-term outcomes from international cohorts of patients with diabetes mellitus. We sought to describe cardiovascular outcomes at 4 years and to identify predictors of these events in patients with diabetes mellitus.

0 comments Cited 176 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: Circulation

Abbreviated Title: Circulation

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Print): 0009-7322

ISSN (Electronic): 1524-4539

Publication date Created: March 18 2019

Publication date (Electronic): March 18 2019

Affiliations

[1 ]TIMI Study Group, Brigham and Women's Hospital, Boston, MA

[2 ]Colorado Prevention Center, CO

[3 ]Internal medicine, Hadassah Hebrew University Hospital, Israel

[4 ]TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

[5 ]Diabetes Unit Devision of Internal Medicine, Hadassah Hebrew University Hospital, Israel

[6 ]Internal Medicine, Hadassah Hebrew University Hospital, Israel

[7 ]Statistics, TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, MA

[8 ]TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, MA

[9 ]Harvard Medical School, Brigham and Women's Hospital Heart and Vascular Center, Boston, MA

[10 ]Medicine, Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, Canada, Canada

[11 ]Internal Medicine-Cardiology, University of Texas-Southwestern Med Ctr, Dallas, TX

[12 ]Institute of Ageing and Chronic Disease, University of Liverpool, United Kingdom

[13 ]Medicine, Brigham and Women's Hospital, Boston, MA

[14 ]Instituto do Coracao (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil

[15 ]GMD, AstraZeneca Gothenburg, Sweden

[16 ]AstraZeneca Gothenburg, Sweden

[17 ]Biopharmaceuticals, AstraZeneca Gothenburg, Sweden

[18 ]Medicine, BWH/TIMI Study Group, Boston, MA

Article

DOI: 10.1161/CIRCULATIONAHA.119.039996

PubMed ID: 30882239

SO-VID: 4947545b-0b94-4cc0-9a0e-7fbee58e66f2

History

Data availability:

Comments

Comment on this article

scite_

Cited by 100

See all cited by

Most referenced authors 1,241

See all reference authors

Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial

Read this article at

Abstract

Related collections

Core Readings in Statistical Mediation Analysis

Most cited references 15

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry.

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 1,175

Cited by 100

Most referenced authors 1,241